Who gets hired and onto which teams
Asimov is hiring eight salaried roles in Boston right now, all hybrid, with compensation ranging from $109,000 to $184,000 and a median of $165,000.
The company builds a mammalian synthetic biology platform where cells, genes, and software are engineered together so designing a living system resembles writing code. That mission shapes every hire. Asimov needs molecular biologists who think like platform engineers, not just run lentiviral transductions. It needs program managers who translate customer therapeutic ambitions into CDMO constraints, not just track Gantt charts. The hiring mix reflects that tension.
The roles cluster into two pillars. On the scientific side, cell line development dominates. These include lentiviral vector, biologics, and viral vector process roles that map directly to Asimov's integrated platform of cells, genes, and software. Analytical development sits beside it, ensuring output meets specs downstream partners depend on. The contractor role at the associate level signals need for scalable bench capacity, while the principal scientist slot indicates a push to deepen technical leadership in biologics.
On the operational side, the Senior Program Manager role sits at the intersection of Commercial and Operations, aligning with the commercial lead on account strategy while coordinating technical operations on execution. The mandate: synthesize feedback from multiple teams into one clear story for partners, own the relationship between what's contracted and what's delivered, and flag scope or cost risks before they surprise anyone. Requirements include seven-plus years in a life-science service organization (CDMOD or CRO), working knowledge of cell line development and biologics process development, and a track record of driving alignment across a matrixed organization without formal authority.
The founders built the company around a culture they call "recombination." The belief is that the mission only works when a diverse team with mixed backgrounds and perspectives works as one. The current hiring slate is that philosophy made concrete: every open role either builds the platform or translates it for customers.
What it pays
Asimov's compensation structure centers on a base-plus-equity model with no formal bonus program. Equity grants serve as the primary variable reward, which means cash compensation stays predictable while upside ties directly to company growth and vesting schedules.
The Zero G Talent board shows a salary band of $109k–$184k across eight salaried roles with a median of $165k. That band aligns with the $145k–$181k range Landed.jobs captured from the same source, and it sits above the $88k–$113k range Salary.com reported as of July 2025. A figure that likely reflects a broader employee population including earlier-career roles not currently advertised.
| Role | Location | Compensation Range | Employment Type |
|---|---|---|---|
| Senior Research Associate/Associate Scientist, Analytical Development (Contractor) | Boston, MA | $40–55/hr | Contractor |
| Scientist, Viral Vector Process Development | Boston, MA | $120K–130K/yr | Full-time |
| Scientist, Lentiviral Vector Cell Line Development | Boston, MA | $120K–130K/yr | Full-time |
| Senior Scientist, Analytical Development | Boston, MA | $145K–165K/yr | Full-time |
| Senior Scientist, Lentiviral Vector Cell Line Development | Boston, MA | $145K–165K/yr | Full-time |
| Senior Scientist, Biologics Cell Line Development | Boston, MA | $145K–165K/yr | Full-time |
| Senior Program Manager | Boston, MA | $160K–181K/yr | Full-time |
| Principal Scientist, Biologics Cell Line Development | Boston, MA | $170K–190K/yr | Full-time |
The progression is clear: entry-level scientist roles open around $120k–$130k, senior scientist positions cluster at $145k–$165k, and the two leadership-track openings — Senior Program Manager and Principal Scientist — push above $160k with the Principal Scientist role topping out at $190k. The lone contractor role, a Senior Research Associate/Associate Scientist in Analytical Development, pays $40–55 per hour, which annualizes to roughly $83k–$114k assuming full-time hours. This is below the salaried band but consistent with contract-market rates for specialized lab talent.
The board's median of $165k lands near the top of the senior scientist cluster, suggesting Asimov's current hiring weight sits at the senior individual-contributor level. Candidates should calibrate cash expectations to the posted base ranges and treat equity as the primary lever for total-compensation growth.
How the hiring process works and what gets candidates through it
Public detail on Asimov's interview loop is sparse. Glassdoor hosts two small clusters of anonymous candidate reports. Three reviews are on the U.S. site and five on the Indian mirror, but only one review breaks down the sequence.
That candidate described a phone screen heavy on behavioral questions plus two technical questions focused on machine-learning model building, followed by a one-on-one with the hiring manager. The manager opened by outlining company goals and the role's scope, then invited the candidate to present prior work. No further rounds are documented in the public reviews.
The first-party board data confirms Asimov is actively hiring: eight salaried roles have appeared on the Zero G Talent board, spanning the contractor role at $40–$55/hr through the Principal Scientist at $170K–$190K/yr, with the Senior Program Manager slot at $160K–$181K/yr. Landed.jobs likewise notes three live postings on Asimov's own careers page as of its latest refresh. The volume and seniority spread suggest a process that scales with role complexity. Contractor screens will differ from principal-scientist loops, but the company has not published a canonical stage map.
What the single detailed review reveals is a pattern familiar in interdisciplinary bio-compute shops: an initial technical-phone filter that probes both domain fluency (here, ML for biological design) and behavioral alignment, then a hiring-manager conversation that doubles as a mutual-pitch session. The manager's choice to lead with strategy and scope signals that Asimov expects candidates to engage with the "why" behind the work, not just the "how." The presentation ask — a walk-through of past projects — tests communication across wet-lab and computational boundaries. This is a core daily demand at a company founded to merge synthetic biology with computer-aided design.
Beyond that, the public record goes quiet. No Bar Raiser equivalent, no published leadership principles, no fixed panel size are documented for Asimov. Candidates should prepare for the phone screen to verify both coding/modeling fundamentals and the ability to explain trade-offs in biological context; for the manager round, bring a concise narrative of a past project that showcases cross-functional collaboration, data-driven iteration, and clear ownership of outcomes. The absence of leaked onsite agendas or take-home assignments in the Glassdoor set may mean later stages are customized per team. It may also simply reflect that few reviewers have reached them. Until Asimov publishes its own guide, treat the phone screen and manager conversation as the only verified gates, and ask your recruiter explicitly what follows.
Where the work happens
Asimov operates out of a permanent Boston facility that houses both laboratory and office space for its cell engineering and biologics development teams. The company's Boston site serves as its primary hub for research and development, supporting the work of its Senior Research Associate/Associate Scientist, Analytical Development (Contractor) and Scientist, Viral Vector Process Development roles, among others.
The Boston location provides access to a dense network of biotech partners and suppliers, which aligns with Asimov's focus on integrated biologics production. In April, Asimov partnered with Cytiva to offer an integrated solution combining Asimov's CHO Edge cell line development platform with Cytiva's HyClone media and feed solutions, as well as Cytiva's Fast Trak process development services, according to Genetic Engineering and Biotechnology News. This collaboration reflects the kind of infrastructure-dependent work that benefits from being co-located with key industry players.
The facility supports hybrid work arrangements, which is reflected in the salary bands listed on the board. These range from $109K to $184K with a median of $165K across 8 salaried roles. These roles include Senior Program Manager and Principal Scientist, Biologics Cell Line Development, indicating that the Boston site accommodates both technical and managerial functions.
The lab spaces at Asimov's Boston facility support the company's core work in genetic circuit design and cell line engineering. This includes the development of lentiviral and viral vector systems, which require specialized biosafety containment and processing equipment. The Scientist, Lentiviral Vector Cell Line Development and Senior Scientist, Lentiviral Vector Cell Line Development positions suggest dedicated vector production and testing capabilities on-site.
Boston's biotech ecosystem provides additional infrastructure support, including shared equipment facilities, specialized suppliers, and regulatory consulting services that complement Asimov's internal capabilities. The company's focus on optimized biologics production benefits from this regional concentration of expertise.
Who thrives here
Asimov's culture selects for builders who treat ambiguity as a design constraint rather than a blocker. The company's own workplace summary frames the defining tradeoff plainly: mission-first urgency drives rapid learning and real partner impact, but demands constant context-switching and tight cross-disciplinary coordination amid evolving priorities. Success hinges on thriving with that ambiguity while communicating across wet lab, modeling, and software to ship shared tools used internally and externally.
The work rhythm reinforces the filter. "Mission first" and "urgency" drive quick decision cycles with extensive context sharing. Employees ship work fast, reprioritize with new data, and rely on transparent updates to stay aligned. Teams build and use CHO Edge, LV Edge, and AAV Edge as a unified platform for internal and partner programs. Designing for both in-house scientists and external customers raises the quality bar and visibility of every result. A candidate who needs a stable, well-scoped brief before moving will struggle; someone who prototypes towards clarity while keeping three disciplines in sync will advance.
Glassdoor reviews echo the pattern. Contributors describe a collaborative atmosphere with supportive colleagues and an exciting mission in synthetic biology, then immediately flag increasing stress levels and overwhelming workloads as the cost of admission. Inspirational leadership and a strong commitment to innovative ideas appear in the same reviews that warn about uneven management, shifting priorities, and weaker perceptions of senior leadership creating execution friction. Promotion paths and career ladders are described as unclear. Advancement feels less predictable than in more structured organizations. The company's BuiltIn summary confirms the career-stagnation signal: unclear ladders make growth feel opaque during scaling phases.
The environment rewards people who can operate without a playbook, translate between biologists and software engineers in the same stand-up, and treat a shifting roadmap as a signal to re-engage rather than a reason to escalate.
First-party board data shows the roles that sit at these intersections. Openings such as Senior Program Manager (Boston, MA) at USD 160K–181K/yr and Principal Scientist, Biologics Cell Line Development (Boston, MA) at USD 170K–190K/yr sit squarely in the cross-disciplinary core. The board's salary band runs $109k–$184k (median $165k) across eight salaried roles, reflecting a compensation structure that rewards technical depth plus coordination scope.
The founders built the company on a CAD-for-biology thesis. Programming cells with the rigor of chip design sets the cultural baseline: the people who thrive here treat biology as an engineering discipline, accept that the platform will break and be rebuilt weekly, and measure progress by whether a partner can run their program on the Edge stack without a Slack thread to the core team.
The hybrid model keeps the feedback loops tight. Two offices, HQ in Cambridge, roughly 95 employees total. You sit near the bioreactors, the compute cluster, and the program managers who translate partner requirements into platform tickets. If that proximity energizes you, the tradeoffs become manageable. If you need predictable scope, formal mentorship ladders, and a firewall between "my job" and "the platform," the friction will compound.
Working in frontier tech? Zero G Talent tracks the openings: see every open Asimov role, browse frontier tech jobs, the companies hiring, and the people building the field.